XML 36 R28.htm IDEA: XBRL DOCUMENT v2.4.0.8
ALLIANCES AND COLLABORATIONS (Tables)
 6 Months Ended
Jun. 30, 2014
Alliances and Collaborations Statement [Line Items]  
Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table Text Block]
Selected financial information pertaining to our alliances was as follows, including net product sales when BMS is the principal in the third-party customer sale for products subject to the alliance. Expenses summarized below do not include all amounts attributed to the activities for the products in the alliance, but only the payments between the alliance partners or the related amortization if the payments were deferred or capitalized.
 
Three Months Ended June 30,
 
Six Months Ended June 30,
Dollars in Millions
2014
 
2013
 
2014
 
2013
Revenues from alliances:
 
 
 
 
 
 
 
Net product sales
$
782

 
$
1,054

 
$
1,677

 
$
2,077

Alliance and other revenues
1,039

 
958

 
1,951

 
1,767

Total Revenues
1,821

 
2,012

 
3,628

 
3,844

 
 
 
 
 
 
 
 
Payments to/(from) alliance partners:
 
 
 
 
 
 
 
Cost of products sold
323

 
338

 
678

 
627

Marketing, selling and administrative
6

 
(27
)
 
3

 
(69
)
Advertising and product promotion
32

 
(7
)
 
67

 
(22
)
Research and development
(4
)
 
(31
)
 
(35
)
 
(55
)
Other (income)/expense
(158
)
 
(100
)
 
(553
)
 
(172
)
 
 
 
 
 
 
 
 
Net earnings/(losses) attributable to noncontrolling interest, pre-tax
7

 
(1
)
 
11

 
23


Selected Alliance Balance Sheet information:
 
 
 
Dollars in Millions
June 30,
2014
 
December 31,
2013
Receivables - from alliance partners
$
1,033

 
$
1,122

Accounts payable - to alliance partners
1,552

 
1,396

Deferred income from alliances(a)
1,958

 
5,089


(a)
Included deferred income classified as liabilities related to assets held-for-sale of $3,671 million at December 31, 2013.
Schedule Of Royalty Rates Based On Net Sales [Table Text Block]
Royalty rates on net sales are as follows:
 
2014
2015
2016
2017 - 2025
Onglyza* and Farxiga* Worldwide Net Sales up to $500 million
44
%
35
%
27
%
12-25%
Onglyza* and Farxiga* Worldwide Net Sales over $500 million
3
%
7
%
9
%
12-25%
Amylin products U.S. Net Sales
—

2
%
2
%
5-12%
AstraZeneca [Member]
  
Alliances and Collaborations Statement [Line Items]  
Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table Text Block]
Summarized financial information related to the AstraZeneca alliances was as follows:
 
Three Months Ended June 30,
 
Six Months Ended June 30,
Dollars in Millions
2014
 
2013
 
2014
 
2013
Revenues from AstraZeneca alliances:
 
 
 
 
 
 
 
Net product sales
$
2

 
$
431

 
$
161

 
$
786

Alliance and other revenues
26

 
5

 
45

 
9

Total Revenues
28

 
436

 
206

 
795

 
 
 
 
 
 
 
 
Payments to/(from) AstraZeneca:
 
 
 
 
 
 
 
Cost of products sold:
 
 
 
 
 
 
 
Profit sharing
1

 
178

 
77

 
324

Amortization of deferred income
—

 
(74
)
 
—

 
(149
)
 
 
 
 
 
 
 
 
Cost reimbursements to/(from) AstraZeneca recognized in:
 
 
 
 
 
 
 
Cost products sold
—

 
(6
)
 
(9
)
 
(9
)
Marketing, selling and administrative
4

 
(34
)
 
(7
)
 
(71
)
Advertising and product promotion
(1
)
 
(7
)
 
(4
)
 
(18
)
Research and development
(2
)
 
(21
)
 
(9
)
 
(43
)
 
 
 
 
 
 
 
 
Other (income)/expense:
 
 
 
 
 
 
 
Amortization of deferred income
(21
)
 
(8
)
 
(34
)
 
(15
)
Provision for restructuring
—

 
(20
)
 
(2
)
 
(25
)
Royalties
(90
)
 
—

 
(138
)
 
—

Transitional services
(34
)
 
—

 
(65
)
 
—

Gain on sale of business
12

 
—

 
(247
)
 
—

 
 
 
 
 
 
 
 
Selected Alliance Cash Flow information:
 
 
 
 
 
 
 
Deferred income
14

 
—

 
289

 
80

Proceeds from sale of business
99

 
—

 
3,154

 
—

Other investing activities
53

 
—

 
53

 
—

Selected Alliance Balance Sheet information:
 
 
 
Dollars in Millions
June 30,
2014
 
December 31,
2013
Deferred income attributed to:
 
 
 
Non-refundable upfront, milestone and other licensing receipts(a)
$
—

 
$
3,671

Assets not yet transferred to AstraZeneca
369

 
—

Services not yet performed for AstraZeneca
260

 
—


(a)
Included in liabilities related to assets held-for-sale at December 31, 2013.